Graft versus. Host, Chemotherapy Dry Eyes Testimonials
Graft Versus Host Testimonial
My Life Became Much Better
I had a bone marrow transplant (using marrow donated by my sister) almost 4 years ago, due to leukemia. I ended up with a very bad case of graft vs. host disease, where my sister’s cells were attacking my soft tissue, skin, mouth and eyes. This has left me with very dry eyes. I virtually had no tears and could not open my eyes without a lot of pain. The graft vs. host has since been treated, but my eyes remained very dry. I went on prescription eye drops and permanent eye plugs, but my eyes were still dry. I finally searched the internet and came across TheraLife. I tried the TheraLife Eye Enhanced therapy along with the Fish Oil. After about 2 months of taking the eye therapy, my eyes and my life became much better. I have been faithfully taking TheraLife Eye for about 2 1/2 years now and I honestly don’t know what I would do without this eye therapy.
Thank you for making such a great product.
*Note: Results may vary.*
V.V.
References
- 1. Socié G, Ritz J. Current issues in chronic graft-vs-host disease. Blood. 2014 Jul 17;124(3):374-84. [PMC free article] [PubMed]
- 2. Antin JH, Kim HT, Cutler C, Ho VT, Lee SJ, Miklos DB, Hochberg EP, Wu CJ, Alyea EP, Soiffer RJ. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood. 2003 Sep 01;102(5):1601-5. [PubMed]
- 3.Shimabukuro-Vornhagen A, Liebig T, von Bergwelt-Baildon M. Statins inhibit human APC function: implications for the treatment of GVHD. Blood. 2008 Aug 15;112(4):1544-5. [PubMed]
- 4.Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM, Maris MB, Storb R. Graft-vs-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003 Jul 15;102(2):756-62. [PubMed]
- 5. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009 May 02;373(9674):1550-61. [PMC free article] [PubMed]
- 6. Jamil MO, Mineishi S. State-of-the-art acute and chronic GVHD treatment. Int J Hematol. 2015 May;101(5):452-66. [PubMed]
- 7. Atkinson K, Horowitz MM, Gale RP, van Bekkum DW, Gluckman E, Good RA, Jacobsen N, Kolb HJ, Rimm AA, Ringdén O. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood. 1990 Jun 15;75(12):2459-64. [PubMed]
- 8. MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A, Ho VT, Bolaños-Meade J, Ferrara JL, Jones R, Arora M, Blazar BR, Holtan SG, Jacobsohn D, Pasquini M, Socie G, Antin JH, Levine JE, Weisdorf DJ. A refined risk score for acute graft-vs-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transplant. 2015 Apr;21(4):761-7. [PMC free article] [PubMed]
- 9. Gale RP, Bortin MM, van Bekkum DW, Biggs JC, Dicke KA, Gluckman E, Good RA, Hoffmann RG, Kay HE, Kersey JH. Risk factors for acute graft-vs-host disease. Br J Haematol. 1987 Dec;67(4):397-406. [PubMed]
- 10. Nassereddine S, Rafei H, Elbahesh E, Tabbara I. Acute Graft vs Host Disease: A Comprehensive Review. Anticancer Res. 2017 Apr;37(4):1547-1555. [PubMed]
References
- 1.
- Socié G, Ritz J. Current issues in chronic graft versus host disease. Blood. 2014 Jul 17;124(3):374-84. [PMC free article] [PubMed]
- 2.
- Antin JH, Kim HT, Cutler C, Ho VT, Lee SJ, Miklos DB, Hochberg EP, Wu CJ, Alyea EP, Soiffer RJ. Sirolimus, tacrolimus, and low-dose methotrexate for graft versus host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood. 2003 Sep 01;102(5):1601-5. [PubMed]
- 3.
- Shimabukuro-Vornhagen A, Liebig T, von Bergwelt-Baildon M. Statins inhibit human APC function: implications for the treatment of GVHD. Blood. 2008 Aug 15;112(4):1544-5. [PubMed]
- 4.
- Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM, Maris MB, Storb R. Graft-versus host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003 Jul 15;102(2):756-62. [PubMed]
- 5.
- Ferrara JL, Levine JE, Reddy P, Holler E. Graft versus host disease. Lancet. 2009 May 02;373(9674):1550-61. [PMC free article] [PubMed]
- 6.
- Jamil MO, Mineishi S. State-of-the-art acute and chronic GVHD treatment. Int J Hematol. 2015 May;101(5):452-66. [PubMed]
- 7.
- Atkinson K, Horowitz MM, Gale RP, van Bekkum DW, Gluckman E, Good RA, Jacobsen N, Kolb HJ, Rimm AA, Ringdén O. Risk factors for chronic graft versus host disease after HLA-identical sibling bone marrow transplantation. Blood. 1990 Jun 15;75(12):2459-64. [PubMed]
- 8.
- MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A, Ho VT, Bolaños-Meade J, Ferrara JL, Jones R, Arora M, Blazar BR, Holtan SG, Jacobsohn D, Pasquini M, Socie G, Antin JH, Levine JE, Weisdorf DJ. A refined risk score for acute graft versus host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transplant. 2015 Apr;21(4):761-7. [PMC free article] [PubMed]
- 9.
- Gale RP, Bortin MM, van Bekkum DW, Biggs JC, Dicke KA, Gluckman E, Good RA, Hoffmann RG, Kay HE, Kersey JH. Risk factors for acute graft-versus-host disease. Br J Haematol. 1987 Dec;67(4):397-406. [PubMed]
- 10.
- Nassereddine S, Rafei H, Elbahesh E, Tabbara I. Acute Graft Versus Host Disease: A Comprehensive Review. Anticancer Res. 2017 Apr;37(4):1547-1555. [PubMed]
- 11.
- Elhage A, Sligar C, Cuthbertson P, Watson D, Sluyter R. Insights into mechanisms of graft versus host disease through humanised mouse models. Biosci Rep. 2022 Sep 30;42(9) [PMC free article] [PubMed]
- 12.
- Várady G, Cserepes J, Németh A, Szabó E, Sarkadi B. Cell surface membrane proteins as personalized biomarkers: where we stand and where we are headed. Biomark Med. 2013 Oct;7(5):803-19. [PubMed]
- 13.
- Salomao M, Dorritie K, Mapara MY, Sepulveda A. Histopathology of Graft vs Host Disease of Gastrointestinal Tract and Liver: An Update. Am J Clin Pathol. 2016 May;145(5):591-603. [PubMed]
- 14.
- Ghimire S, Weber D, Mavin E, Wang XN, Dickinson AM, Holler E. Pathophysiology of GvHD and Other HSCT-Related Major Complications. Front Immunol. 2017;8:79. [PMC free article] [PubMed]
- 15.
- Lee SJ, Vogelsang G, Flowers ME. Chronic graft versus host disease. Biol Blood Marrow Transplant. 2003 Apr;9(4):215-33. [PubMed]
- 16.
- Elad S, Zadik Y, Zeevi I, Miyazaki A, de Figueiredo MA, Or R. Oral cancer in patients after hematopoietic stem-cell transplantation: long-term follow-up suggests an increased risk for recurrence. Transplantation. 2010 Dec 15;90(11):1243-4. [PubMed]
- 17.
- Gálvez K, Muñoz P, Vera V, Arce C. Vitiligo type cutaneous manifestation of chronic graft versus host disease. Case report. Rev Chil Pediatr. 2018 Feb;89(1):113-117. [PubMed]
- 18.
- Gandelman JS, Zic J, Dewan AK, Lee SJ, Flowers M, Cutler C, Pidala J, Chen H, Jagasia MH, Tkaczyk ER. The Anatomic Distribution of Skin Involvement in Patients with Incident Chronic Graft versus Host Disease. Biol Blood Marrow Transplant. 2019 Feb;25(2):279-286. [PMC free article] [PubMed]
- 19.
- Munir SZ, Aylward J. A Review of Ocular Graft Versus Host Disease. Optom Vis Sci. 2017 May;94(5):545-555. [PubMed]
- 20.
- 21.
- Firoz BF, Lee SJ, Nghiem P, Qureshi AA. Role of skin biopsy to confirm suspected acute graft versus host disease: results of decision analysis. Arch Dermatol. 2006 Feb;142(2):175-82. [PubMed]
- 22.
- Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, Zhang Q, Wong CH, Wang H, Chin A, Gomez A, Harris AC, Levine JE, Choi SW, Couriel D, Reddy P, Ferrara JL, Paczesny S. ST2 as a marker for risk of therapy-resistant graft versus host disease and death. N Engl J Med. 2013 Aug 08;369(6):529-39. [PMC free article] [PubMed]
- 23.
- Ferrara JL, Harris AC, Greenson JK, Braun TM, Holler E, Teshima T, Levine JE, Choi SW, Huber E, Landfried K, Akashi K, Vander Lugt M, Reddy P, Chin A, Zhang Q, Hanash S, Paczesny S. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood. 2011 Dec 15;118(25):6702-8. [PMC free article] [PubMed]
- 24.
- Korngold R, Marini JC, de Baca ME, Murphy GF, Giles-Komar J. Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses. Biol Blood Marrow Transplant. 2003 May;9(5):292-303. [PubMed]
- 25.
- Matsukuma KE, Wei D, Sun K, Ramsamooj R, Chen M. Diagnosis and differential diagnosis of hepatic graft versus host disease (GVHD). J Gastrointest Oncol. 2016 Apr;7(Suppl 1):S21-31. [PMC free article] [PubMed]
- 26.
- Naymagon S, Naymagon L, Wong SY, Ko HM, Renteria A, Levine J, Colombel JF, Ferrara J. Acute graft-versus-host disease of the gut: considerations for the gastroenterologist. Nat Rev Gastroenterol Hepatol. 2017 Dec;14(12):711-726. [PMC free article] [PubMed]
- 27.
- Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED. Clinical manifestations of graft versus host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974 Oct;18(4):295-304. [PubMed]
- 28.
- Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ, Cahn JY, Calderwood S, Gratwohl A, Socié G, Abecasis MM, Sobocinski KA, Zhang MJ, Horowitz MM. IBMTR Severity Index for grading acute graft versus host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997 Jun;97(4):855-64. [PubMed]
- 29.
- Cho C, Hsu M, Barba P, Maloy MA, Avecilla ST, Barker JN, Castro-Malaspina H, Giralt SA, Jakubowski AA, Koehne G, Meagher RC, O'Reilly RJ, Papadopoulos EB, Ponce DM, Tamari R, van den Brink MRM, Young JW, Devlin SM, Perales MA. Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis. Bone Marrow Transplant. 2017 Dec;52(12):1629-1636. [PMC free article] [PubMed]
- 30.
- Cahn JY, Klein JP, Lee SJ, Milpied N, Blaise D, Antin JH, Leblond V, Ifrah N, Jouet JP, Loberiza F, Ringden O, Barrett AJ, Horowitz MM, Socié G., Société Française de Greffe de Moëlle et Thérapie Cellulaire. Dana Farber Cancer Institute. International Bone Marrow Transplant Registry. Prospective evaluation of 2 acute graft versus host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood. 2005 Aug 15;106(4):1495-500. [PMC free article] [PubMed]
- 31.
- Müller JA, Zirafi O, Roan NR, Lee SJ, Münch J. Evaluation of EPI-X4 as a urinary peptide biomarker for diagnosis and prognosis of late acute GvHD. Bone Marrow Transplant. 2016 Aug;51(8):1137-9. [PMC free article] [PubMed]
- 32.
- Bergeron A, Cheng GS. Bronchiolitis Obliterans Syndrome and Other Late Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation. Clin Chest Med. 2017 Dec;38(4):607-621. [PubMed]
- 33.
- van der Meij BS, de Graaf P, Wierdsma NJ, Langius JA, Janssen JJ, van Leeuwen PA, Visser OJ. Nutritional support in patients with GVHD of the digestive tract: state of the art. Bone Marrow Transplant. 2013 Apr;48(4):474-82. [PubMed]
- 34.
- Mays JW, Fassil H, Edwards DA, Pavletic SZ, Bassim CW. Oral chronic graft versus host disease: current pathogenesis, therapy, and research. Oral Dis. 2013 May;19(4):327-46. [PMC free article] [PubMed]